Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Quiescence, Stemness and Adipogenic Differentiation Capacity in Human DLK1 - /CD34 + /CD24 + Adipose Stem/Progenitor Cells.

Hatzmann FM., Ejaz A., Wiegers GJ., Mandl M., Brucker C., Lechner S.

Laboratory Study on Face & Skin, published in Cells (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Cells (2021)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
33498986
PMCID
PMC7912596
DOI
10.3390/cells10020214
Citations
19

Abstract (original English)

We explore the status of quiescence, stemness and adipogenic differentiation capacity in adipose stem/progenitor cells (ASCs) ex vivo, immediately after isolation from human subcutaneous white adipose tissue, by sorting the stromal vascular fraction into cell-surface DLK1 + /CD34 - , DLK1 + /CD34 dim and DLK1 - /CD34 + cells. We demonstrate that DLK1 - /CD34 + cells, the only population exhibiting proliferative and adipogenic capacity, express ex vivo the bonafide quiescence markers p21 Cip1 , p27 Kip1 and p57 Kip2 but neither proliferation markers nor the senescence marker p16 Ink4a . The pluripotency markers NANOG, SOX2 and OCT4 are barely detectable in ex vivo ASCs while the somatic stemness factors, c-MYC and KLF4 and the early adipogenic factor C/EBPβ are highly expressed. Further sorting of ASCs into DLK1 - /CD34 + /CD24 - and DLK1 - /CD34 + /CD24 + fractions shows that KLF4 and c-MYC are higher expressed in DLK1 - /CD34 + /CD24 + cells correlating with higher colony formation capacity and considerably lower adipogenic activity. Proliferation capacity is similar in both populations. Next, we show that ASCs routinely isolated by plastic-adherence are DLK1 - /CD34 + /CD24 + . Intriguingly, CD24 knock-down in these cells reduces proliferation and adipogenesis. In conclusion, DLK1 - /CD34 + ASCs in human sWAT exist in a quiescent state, express high levels of somatic stemness

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipogenesisAdipose Tissue, WhiteAntigens, CD34BiomarkersCCAAT-Enhancer-Binding Protein-betaCD24 AntigenCalcium-Binding ProteinsCell CycleCell ProliferationCells, Cultured

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research